Albert Topf, Moritz Mirna, Uta C Hoppe, Michael Lichtenauer, Lukas Motloch, Ravi Vazirani, Sabine Horn, Iván J Núñez-Gil
{"title":"Takotsubo Syndrome Recurrence, a Trigger for Increased 30-Day Cardiovascular Mortality.","authors":"Albert Topf, Moritz Mirna, Uta C Hoppe, Michael Lichtenauer, Lukas Motloch, Ravi Vazirani, Sabine Horn, Iván J Núñez-Gil","doi":"10.1159/000545544","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Recurrence of Takotsubo syndrome (TTS) has been reported with a rate up to 4 %. The effect of TTS recurrence on clinical outcomes has not been in the focus of studies so far.</p><p><strong>Methods: </strong>In our study, we enrolled 435 patients with TTS, of whom 14 patients had a recurrence. The inclusion interval for the index event was from 2015 to 2022 and patients were followed to categorize them in the group of TTS with or without the recurrence. TTS recurrences were registered until 06/2024. Blood samples, data on clinical presentation, precipitating factors, cardiovascular risk factors, medications, demographics, echocardiographic and electrocardiographic parameters were obtained. The 30-day -cardiovascular mortality (CV), the 30-day mortality and arrhythmia during hospitalization were evaluated.</p><p><strong>Results: </strong>Co-morbidities, ECG changes, pre-medication and symptoms were not significantly different between TTS patients with and without recurrence. Only the index left-ventricular ejection fraction (LVEF) of TTS patients with recurrence was significantly decreased (p = 0.046). In the case of outcome parameters, TTS patients with recurrence had a significantly, higher 30-day-CV mortality compared to those without recurrence (21.4 % vs 3.8 %, p = 0.001) with a 5.9-fold higher 30-day-CV mortality ((B(SE)= 1.94(0.70), p = 0.001)).</p><p><strong>Conclusion: </strong>In our study, the TTS recurrence was associated with 5.9-fold higher 30 day-CV mortality. Therefore, a more precise monitoring is necessary in this high-risk group. Whether only, the reduced LVEF is responsible for the increased 30-day-CV mortality, is an open issue and more factors can be assumed to play a role.</p>","PeriodicalId":18455,"journal":{"name":"Medical Principles and Practice","volume":" ","pages":"1-14"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Principles and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545544","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Recurrence of Takotsubo syndrome (TTS) has been reported with a rate up to 4 %. The effect of TTS recurrence on clinical outcomes has not been in the focus of studies so far.
Methods: In our study, we enrolled 435 patients with TTS, of whom 14 patients had a recurrence. The inclusion interval for the index event was from 2015 to 2022 and patients were followed to categorize them in the group of TTS with or without the recurrence. TTS recurrences were registered until 06/2024. Blood samples, data on clinical presentation, precipitating factors, cardiovascular risk factors, medications, demographics, echocardiographic and electrocardiographic parameters were obtained. The 30-day -cardiovascular mortality (CV), the 30-day mortality and arrhythmia during hospitalization were evaluated.
Results: Co-morbidities, ECG changes, pre-medication and symptoms were not significantly different between TTS patients with and without recurrence. Only the index left-ventricular ejection fraction (LVEF) of TTS patients with recurrence was significantly decreased (p = 0.046). In the case of outcome parameters, TTS patients with recurrence had a significantly, higher 30-day-CV mortality compared to those without recurrence (21.4 % vs 3.8 %, p = 0.001) with a 5.9-fold higher 30-day-CV mortality ((B(SE)= 1.94(0.70), p = 0.001)).
Conclusion: In our study, the TTS recurrence was associated with 5.9-fold higher 30 day-CV mortality. Therefore, a more precise monitoring is necessary in this high-risk group. Whether only, the reduced LVEF is responsible for the increased 30-day-CV mortality, is an open issue and more factors can be assumed to play a role.
目的:Takotsubo综合征(TTS)的复发率高达4%。TTS复发对临床预后的影响目前还不是研究的重点。方法:在我们的研究中,我们纳入了435例TTS患者,其中14例复发。指标事件的纳入时间间隔为2015 - 2022年,随访患者并将其分为有无复发的TTS组。TTS复发记录到2024年6月。获得血液样本、临床表现、诱发因素、心血管危险因素、药物、人口统计学、超声心动图和心电图参数等数据。观察住院30天心血管死亡率(CV)、30天死亡率和心律失常。结果:有无复发TTS患者的合并症、心电图改变、用药前及症状无显著差异。复发TTS患者仅左室射血分数指数(LVEF)显著降低(p = 0.046)。在结果参数方面,复发的TTS患者的30天cv死亡率明显高于无复发的TTS患者(21.4% vs 3.8%, p = 0.001), 30天cv死亡率高出5.9倍(B(SE)= 1.94(0.70), p = 0.001)。结论:在我们的研究中,TTS复发与5.9倍高的30天cv死亡率相关。因此,对这一高危人群进行更精确的监测是必要的。是否仅仅是LVEF的降低导致了30天cv死亡率的增加,这是一个悬而未决的问题,可以假设有更多的因素在起作用。
期刊介绍:
''Medical Principles and Practice'', as the journal of the Health Sciences Centre, Kuwait University, aims to be a publication of international repute that will be a medium for dissemination and exchange of scientific knowledge in the health sciences.